Takeda formally completes Shire acquisition

8 January 2019
takeda_big

Japan’s Takeda Pharmaceutical (TYO: 4502) has announced the formal completion of its $62 billion acquisition of the rare disease specialist Shire.

Operating in around 80 countries or regions, the newly-formed entity will have global revenues of over $30 billion, and will focus on four main therapeutic areas - oncology, gastroenterology, neuroscience and rare diseases.

Chief executive Christophe Weber said he was “pleased to have completed the acquisition several months earlier than expected,” adding that the company seeks to deliver “highly-innovative medicines to patients around the world with expanded scale and geographical footprint.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical